Trial intelligence / Profile preview

Gilteritinib vs Gilteritinib + Azacitidine vs Azacitidine in Newly Diagnosed FLT3-mutated AML Not Eligible for Intensive Chemotherapy

2024-512474-98-00Phase 3Completed

Sponsor

Astellas Pharma

Start

Jun 2024

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

3